Ori CAR 017
Alternative Names: GPRC5D-CAR-T; Ori-CAR-017Latest Information Update: 11 Jun 2024
At a glance
- Originator OriCell Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Multiple myeloma
Most Recent Events
- 06 Jun 2024 Updated efficacy, adverse events and pharmacokinetics data from a phase I POLARIS trial in Multiple myeloma released by OriCell Therapeutics
- 31 May 2024 Efficacy, adverse events and pharmacokinetics data from phase-I POLARIS trial in Multiple myeloma presented at the60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 03 Apr 2024 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT06271252)